Molecule for all forms of multiple sclerosis

Orelabrutinib is a new oral drug, Bruton's tyrosine kinase (BTK) inhibitor. It is believed that by blocking BTK in the brain, this drug will be able to inhibit the effector functions of myeloid and B cells, thereby slowing the progression of the disease and improving the functionality of patients with all forms of multiple sclerosis.

Considering the complex and chronic nature of multiple sclerosis, it can be seen that the unique characteristics of orelabrutinib, which combines high selectivity and permeability in the central nervous system, provides this molecule with clinical advantages compared to other programs aimed at BTK.

Source: endpts